
Eli Lilly and Company, Novo Nordisk A/S, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. “Pharmaceutical stocks” are shares of companies that develop, manufacture, market, and sell prescription drugs, over-the-counter medicines, and related healthcare products. For stock market investors, these stocks offer exposure to the healthcare sector and can be influenced by factors such as drug approvals, clinical trial results, patents, regulations, and demand for medical treatments. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Read Our Latest Research Report on NVO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read Our Latest Research Report on ABBV
Featured Articles
- MarketBeat’s Top Five Stocks to Own in May 2026
- IREN Is Flipping the Switch from Bitcoin to AI
- This Quantum Computing Stock May Be Closer to a Breakout Than You Think
- RTX Is Set to Revolutionize Munitions Manufacturing
- Microsoft Is Spending Billions on AI, But Investors Aren’t Buying It
- Is Co-Diagnostics National Security’s Next Diagnostic Pick?
